AIM - AIM ImmunoTech Inc
IEX Last Trade
0.3481
-0.012 -3.390%
Share volume: 131,020
Last Updated: Fri 30 Aug 2024 09:35:34 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$0.36
-0.01
-3.28%
View ratios
Fiscal Date | 2022-06-30 | 2022-09-30 | 2022-12-31 | 2023-03-31 | 2023-06-30 | 2023-09-30 | 2023-12-31 | 2024-03-31 | |
---|---|---|---|---|---|---|---|---|---|
Fiscal Quarter | Q2 2022 | Q3 2022 | Q4 2022 | Q1 2023 | Q2 2023 | Q3 2023 | Q4 2023 | Q1 2024 | |
Report Date | 2022-08-15 | 2022-11-14 | 2023-03-31 | 2023-05-15 | 2023-08-14 | 2023-11-14 | 2024-04-01 | 2024-05-15 | |
Total revenue | 30.000 K | 21.000 K | 57.000 K | 49.000 K | 42.000 K | 46.000 K | 65.000 K | 40.000 K | |
Cost of revenue | 69.000 K | 0.000 | -146.000 K | 0.000 | 0.000 | 30.000 K | 12.000 K | 8.000 K | |
Gross profit | -39.000 K | 21.000 K | 203.000 K | 49.000 K | 42.000 K | 16.000 K | 53.000 K | 32.000 K | |
153.85% | 866.67% | -75.86% | -14.29% | -61.90% | 231.25% | -39.62% | |||
Operating expenses | 4.656 M | 6.542 M | 5.758 M | 4.344 M | 5.503 M | 8.173 M | 14.056 M | 5.766 M | |
Selling general and admin | 2.181 M | 5.170 M | 3.651 M | 2.292 M | 2.550 M | 5.439 M | 10.856 M | 3.815 M | |
Research and development | 2.475 M | 1.372 M | 2.107 M | 2.052 M | 2.953 M | 2.734 M | 3.200 M | 1.951 M | |
Total expenses | 4.725 M | 6.542 M | 5.612 M | 4.344 M | 5.503 M | 8.203 M | 14.068 M | 5.774 M | |
38.46% | -14.22% | -22.59% | 26.68% | 49.06% | 71.50% | -58.96% | |||
Operating income | -4.695 M | -6.521 M | -5.555 M | -4.295 M | -5.461 M | -8.157 M | -14.003 M | -5.734 M | |
Ebit | -4.695 M | -6.521 M | -5.555 M | -4.295 M | -5.461 M | -8.157 M | -14.003 M | -5.734 M | |
Pretax income | -4.851 M | -6.385 M | -4.389 M | -3.661 M | -4.909 M | -7.816 M | -12.576 M | -5.817 M | |
31.62% | -31.26% | -16.59% | 34.09% | 59.22% | 60.90% | -53.75% | |||
Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
Net income basic | -4.851 M | -6.385 M | -4.389 M | -3.661 M | -4.909 M | -7.816 M | -12.576 M | -5.817 M | |
-31.62% | 31.26% | 16.59% | -34.09% | -59.22% | -60.90% | 53.75% | |||
Net income | -4.851 M | -6.385 M | -4.389 M | -3.661 M | -4.909 M | -7.816 M | -12.576 M | -5.817 M | |
-31.62% | 31.26% | 16.59% | -34.09% | -59.22% | -60.90% | 53.75% |